Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anika Therapeutics (ANIK) Gains from Sales and Divestitures (2016 - 2025)

Historic Gains from Sales and Divestitures for Anika Therapeutics (ANIK) over the last 14 years, with Q2 2025 value amounting to $311335.0.

  • Anika Therapeutics' Gains from Sales and Divestitures rose 427.43% to $311335.0 in Q2 2025 from the same period last year, while for Jun 2025 it was $311335.0, marking a year-over-year increase of 427.43%. This contributed to the annual value of $311441.0 for FY2024, which is 1889.83% up from last year.
  • Latest data reveals that Anika Therapeutics reported Gains from Sales and Divestitures of $311335.0 as of Q2 2025, which was up 427.43% from $250172.0 recorded in Q1 2025.
  • Over the past 5 years, Anika Therapeutics' Gains from Sales and Divestitures peaked at $311441.0 during Q4 2024, and registered a low of $87953.0 during Q1 2022.
  • Over the past 5 years, Anika Therapeutics' median Gains from Sales and Divestitures value was $248542.5 (recorded in 2023), while the average stood at $213685.8.
  • Per our database at Business Quant, Anika Therapeutics' Gains from Sales and Divestitures skyrocketed by 215032.5% in 2021 and then rose by 18.26% in 2025.
  • Over the past 5 years, Anika Therapeutics' Gains from Sales and Divestitures (Quarter) stood at $91680.0 in 2021, then soared by 79.07% to $164167.0 in 2022, then surged by 59.56% to $261939.0 in 2023, then rose by 18.9% to $311441.0 in 2024, then dropped by 0.03% to $311335.0 in 2025.
  • Its last three reported values are $311335.0 in Q2 2025, $250172.0 for Q1 2025, and $311441.0 during Q4 2024.